Inalacor Accuhaler

Fluticasone propionate, the active ingredient in Inalacor Accuhaler, is a corticosteroid presented as a dry powder inhaler for inhalation use. It reduces airway inflammation and hyper‑responsiveness, and is indicated for the long‑term management of asthma and chronic obstructive pulmonary disease (COPD) in adults and adolescents.

GNH USA supplies Inalacor Accuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to a global network of healthcare providers.

Fluticasone propionate is a corticosteroid inhaled to control airway inflammation in respiratory diseases.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps maintain lung function. - Bronchial hyperresponsiveness: reduces airway sensitivity to triggers, supporting overall respiratory stability.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth. - Hoarseness or dysphonia: voice changes due to local irritation. - Cough or throat irritation: mild respiratory discomfort. - Headache: transient pain often unrelated to systemic exposure.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.

Before initiating therapy, consider the following precautions: - Assess infection risk: evaluate for active respiratory infections prior to use. - Monitor growth in children: periodic assessment of height velocity is recommended. - Avoid abrupt discontinuation: taper the dose after long‑term therapy to prevent adrenal insufficiency. - Use mouth rinse: rinse and expectorate after inhalation to reduce oral candidiasis. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Fluticasone propionate may interact with other medicines as follows:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic corticosteroid exposure. - Systemic corticosteroids: additive immunosuppressive effects. - Live vaccines: reduced efficacy and increased infection risk.

Moderate Interactions (Monitor Closely): - Beta‑agonists: may mask bronchospasm symptoms. - Diuretics: potential for hypokalemia when combined with systemic steroids. - Antifungal azoles (moderate inhibitors): may modestly raise fluticasone levels.